Veracyte. has been granted a patent for a method that differentiates between usual interstitial pneumonia (UIP) and non-UIP. The method involves pooling lung tissue samples, assaying for specific gene expression markers, and classifying the samples based on the results. GlobalData’s report on Veracyte gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Veracyte, ML-based biomarker screening was a key innovation area identified from patents. Veracyte's grant share as of June 2024 was 26%. Grant share is based on the ratio of number of grants to total number of patents.
Method for identifying usual interstitial pneumonia (uip) vs non-uip
The patent US11976329B2 outlines a method for distinguishing between usual interstitial pneumonia (UIP) and non-usual interstitial pneumonia (non-UIP) in subjects suspected of having these conditions. The method involves pooling lung tissue samples from the subject to create a composite sample, which is then assayed for the expression levels of specific genetic markers associated with UIP and non-UIP. A classification is generated based on these expression levels, determining whether the sample is positive for UIP or non-UIP. The method emphasizes the use of a trained algorithm to enhance accuracy, with claims indicating that classifications can achieve an accuracy of at least 90%, alongside specific sensitivity and specificity thresholds.
Additionally, the method allows for the incorporation of various factors, such as smoking status, into the analysis. It includes provisions for using a weighted algorithm that can account for markers influenced by smoking, ensuring that the classification remains robust. The patent also specifies that the pooled lung tissue sample can be derived from various sources, including biopsy samples and bronchoalveolar lavage samples. The markers identified for analysis encompass a wide range of genes, providing a comprehensive approach to the classification of lung tissue samples. This method aims to improve diagnostic accuracy for interstitial pneumonia, potentially aiding in better patient management and treatment strategies.
To know more about GlobalData’s detailed insights on Veracyte, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
